A Randomized, Double-masked, Phase 3 Study of ABP 938 Efficacy and Safety Compared to Aflibercept (Eylea®) in Subjects with Neovascular Age-related Macular Degeneration.

PI: Itamar Klemperer. Funded: Praxell

A Phase 3, Multicentre, Double-masked, Randomised Study to Evaluate the Efficacy and Safety of Intravitreal OPT-302 in Combination with Ranibizumab, Compared with Ranibizumab Alone, in Participants with Neovascular Age-related Macular Degeneration (nAMD) - ShORe

PI: Aviel Hadad. Funded: IQVIA

A 52-week multicenter, randomized, double-masked, 2-arm parallel study to compare efficacy, safety and immunogenicity of SOK583A1 to Eylea®, administered intravitreally, in patients with neovascular age-related macular degeneration (CSOK583A12301).

PI: Ruth Shreiber. Funded: Syneos Health Clinical Ltd.

Prospective, Feasibility Study To Evaluate The Safety Of The EndoArt® For Treatment Of Subjects Suffering From Corneal Edema.

PI: Boris Knyazer. Funded: Novatrials

MULTICENTER, RANDOMIZED, VISUAL ASSESSOR-MASKED STUDY OF THE EFFECTIVENESS AND SAFETY OF A 36-WEEK REFILL REGIMEN FOR THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB VS AFLIBERCEPT TREAT & EXTEND IN SUBJECTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (DIAGRID)

PI: Noam Yankelevich. Funded: Roche

Retrospective Chart Review Study Combined with Cross sectional Patient and Caregiver Surveys to Document and Describe the Disease-related Clinical, Individual, Sociodemographic Characteristics of Patients with X-linked Retinitis Pigmentosa (XLRP) and the Impact of XLRP on Patients and Their Caregivers

PI: Aviel Hadad. Funded: Janssen EMEA

Macula edema due to retinal vein occlusion

PI: Noam Yankelevich. Funded: Bayer patexel

Oftac eye drops in active non infectious anterior uvetitis patients

PI: Marina Shnek. Funded: Bionanosim(BNS) ltd